4 December 2024 - Today, the Biden-Harris Administration announced that two drug manufacturers with FDA approved gene therapies for sickle cell disease have entered into agreements with the Centers for Medicare & Medicaid Services to participate in the Cell and Gene Therapy Access Model.

The voluntary model, led by the Center for Medicare and Medicaid Innovation, will test outcomes based agreements for cell and gene therapies, with the aim to improve health outcomes, increase access to cell and gene therapies, and lower health care costs. These outcomes based agreements will tie payments to whether the therapy improves health outcomes for people with Medicaid who receive these drugs.

Read CMS press release